ALK-pozitivnyy nemelkokletochnyy rak legkogo i metody ego lecheniya: obzor literatury


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

ALK gene rearrangemen tis detected in 3-5% of cases of non-small cell lung cancer (NSCLC). Crizotinib is the first multi-kinase ALK, ROS1 and MET inhibitor registered in Russia for the treatment of patients with ALK-positive NSCLC. Its efficacy and advantage over standard chemotherapy is proved by the results of randomized clinical trials in both the first and second-line treatment according to the criteria of objective response and time to progression. Analysis of the effectiveness of crizotinib in patients with brain metastases revealed a significant correlation (p<0.001) between the systemic and intracranial control for tumor growth. The basic mechanisms of acquired resistance to crizotinib are already defined, and now researchers are looking for ways to overcome them. Clinical studies are evaluating several drugs - second generation ALK inhibitors.

Full Text

Restricted Access

References

  1. Solomon B, Varella-Garcia M., Cambridge D.R. ALK gene reaarangerements : a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 2009;4:1450.
  2. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S., Costa D., Heist R., Solomon B., Stubbs H., Admane S., McDermott U,Settleman J., Kobayashi S., Mark E.J., Rodig S.J., Chirieac L., Kwak E., Lynch T., Iafrate J. Clinical features and outcome of patients with non-small cell cancer who harbor EML4-ALK. J. Clin. Oncol. 2009:27:4247-53.
  3. Food and Drug Administration http://www. accessdata.fda.gov/drugsatfda_docs/ label/2011/202570s000lbl.pdf.
  4. http://seer.cancer.gov/statfacts/html/lungb. html accessed on September 03, 2014.
  5. Inamura K., Takeuchi K., Togashi Y., Hatano S., Ninomiya H., Motoi N., Mun M., Sakao Y., Okumura S., Nakagawa K., Soda M., Choi Y., Mano H., Ishikawa Y. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J. Thorac. Oncol. 2008:3:13.
  6. Shaw A.T., Kim D.W., Nakagawa K., Seto T. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013;368(25):2385-94.
  7. Solomon B.J., Mok T., Kim D.W. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014;371 (23):2167-77.
  8. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early successes and future challenges. Nat. Rev. Clin. Oncol. 2012;9:268-77.
  9. Fontana D., Ceccon M., Gambacorti-Passerini C., Mologni L. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Med. 2015;4(7):953-65.
  10. Gehrmann M. Drug evaluation: STA-4783 -enhancing taxane efficacy by induction of Hsp70. Curr. Opin. Investig. Drugs. 2006;7(6):574-79.
  11. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., Kondo K.L., Linderman D., Heasley L.E., Franklin V.A., Varella-Garcia M., Camidge D.R. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 2012;18(5):1472-82.
  12. Katayama R., Shaw A.T., Khan T.M. Mechanisms of acquired crizotinib resistance in ALK rearranged lung cancers. Sci. Transl. Med. 2012;4(120):120ra17.
  13. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B, Jessop N.A., Wain J.C., Yeo A.T., Benes C., Drew L., Saeh J.C., Crosby K., Sequist L.V., Iafrate A.J., Engelman J.A. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc. Natl. Acad. Sci. USA. 2011;108(18):7535-40
  14. Weickhardt A.J., Rothman M.S., Salian-Mehta S., Kiseljak-Vassiliades K., Oton A., Doebele R.C., Wierman M.E., Camidge D.R. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic non-small cell lung cancer. Cancer. 2012;118(21):5302-09.
  15. Koivunen J.P., Mermel C., Zejnullahu K., Murphy K., Lifshits E., Holmes A.J., Choi H.J., Kim J., Chiang D., Thomas R., Lee J., Richards W.G., Sugarbaker D.J., Ducko C., Lindeman N., Marcoux J.P., Engelman J.A., Gray N.S., Lee C., Meyerson M.,Jаnne P.A. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008;14:4275-83.
  16. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., Lathan C., Marcoux J.P., Du J., Okuda K., Capelletti M., Shimamura T., Ercan D., Stumpfova M., Xiao Y., Weremowicz S., Butaney M., Heon S., Wilner K., Christensen J.G., Eck M.J., Wong K-K., Lindeman N., Gray N., Rodig S.J., Jаnne P.A. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71: 6051-60.
  17. Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., Kaneda H., Takezawa K., Kuwata K., Yamaguchi H., Hatashita E., Nishio K., Nakagawa K. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4- ALK-positive non-small cell lung cancer. Clin. Cancer Res. 2012;18: 6219-26.
  18. Бредер В.В., Лактионов К.К. ALK- позитивный немелкоклеточный рак легкого: возможности лекарственного лечения. Газета общества онкологов-химиотерапевтов. 2014 (1).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies